Protocol (c ) H8H -MC-LAHU  
 
 
A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular 
Effect of Single Oral Doses of Lasmiditan when Coadministered with Single Oral Doses of 
Sumatriptan in Healthy Subjects  
 
[STUDY_ID_REMOVED] 
 Approval Date: 20- Oct-2017 
 
 
 
H8H- MC- LAHU(c )  C l in ica l  Pha rmaco logy  P ro toco l Page  1
LY573144P ro toco l  H8H- MC- LAHU(c )
A  Random i zed ,  Doub le- B l ind ,  Fou r- Pe r iod ,  C rossove r  
S tudy to  Eva lua te  the  Ca rd iovascu la r  E f fec t  o f  S ing le  O ra l  
Doses  o f  Lasm id i tan  when  Coadm in is te red  w i th  S ing le  
O ra l  Doses  o f  Suma t r ip tan  in  Hea l thy Sub jec ts
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ie s  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
LY573144,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  and  
Company  o r  i ts  subs id ia r ies .
No te  to  Regu la to ry  Au tho r i t ies :  This  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .   E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .   In  
the  Un i ted  S ta tes ,  th is  do cumen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  Exemp t ion  4  and  
may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  app rova l  o f  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies .
App ro va l  Da te :  20 -O c t -2017  GMTLasm id i tan(LY 573144 )
E l i  L i l l y  and  Compan y
Ind ianapo l is ,  Ind iana  U SA  [ZIP_CODE]
C l in i ca l  Pha rma co log y  P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  Li l ly :   
17Augus t2017 .
Amendmen t  (a )  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly :  26  Sep tembe r  2017
Amendmen t  (b )  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly :  10  O c tobe r  2017
Amendmen t  (c)  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly  on  app ro va l  da te  p ro v ided  
be low .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178750] of Single Oral Doses of 
Lasmiditan when Coadministered with Single Oral Doses of 
Sumatriptan in Healthy  Subjects
Section Page
Protocol  H8H -MC-LAHU(c) A Rando mized, Double -Blind, Four -Period, 
Crossover Study  to Eval uate the Car diovascular Effect of Single Oral 
Doses of Lasmiditan when Coadministered with Single Oral Doses 
of Sum atriptan in Heal thy Subjects ..................................................................................... [ADDRESS_178751] ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale ............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_178752] yle and/or Dietary Requirements ......................................................................... 24
6.3.1. Meals and Dietary  Restri ctions............................................................................. 24
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 24
6.3.3. Activity................................................................................................................ 25
6.4. Screen Failures ............................................................................................................. 25
7. Treat ment .......................................................................................................................... 26
7.1. Treatment Administered ............................................................................................... 26
7.1.1. Packaging and Labeling ....................................................................................... 26
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 3
LY5731447.2. Method of Treatment Assignment ................................................................................ 26
7.2.1. Timing of Doses ................................................................................................... 27
7.3. Blinding ....................................................................................................................... 27
7.4. Dose Modificat ion........................................................................................................ 27
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_178753] to Follow -Up.......................................................................................... 30
9. Study  Assessments and Procedures ................................................................................... 31
9.1. Efficacy Assessments ................................................................................................... 31
9.2. Adverse Events ............................................................................................................ 31
9.2.1. Serious Adverse Events ........................................................................................ 32
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 32
9.2.2. Com plaint Handling ............................................................................................. 33
9.3. Treatment of Overdose .................................................................................................33
9.4. Safety........................................................................................................................... 33
9.4.1. Laboratory  Tests .................................................................................................. 33
9.4.2. Vital Signs ........................................................................................................... 33
[IP_ADDRESS]. Supi[INVESTIGATOR_154509] .................................................................. 33
[IP_ADDRESS]. Ambulatory  Blood Pressure Moni toring.......................................................... 34
9.4.3. Electrocardiograms .............................................................................................. 34
9.4.4. Safety Moni toring ................................................................................................ 35
[IP_ADDRESS]. Hepati c Safet y................................................................................................ 35
9.5. Pharmacokinet ics......................................................................................................... 35
9.5.1. Bioanalysis ........................................................................................................... 36
9.6. Pharmacodynamics ...................................................................................................... 36
9.7. Genet ics....................................................................................................................... 36
9.8. Biomarker s................................................................................................................... 36
9.8.1. Creatinine Clearance ............................................................................................ 36
9.8.2. Renal Bio marker Samples .................................................................................... 37
9.9. Heal th Economics ........................................................................................................ 37
10. Statistical Considerations and Data Analysis ..................................................................... 38
10.1. Sample Si ze Determinat ion.......................................................................................... 38
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178754] ics.......................................................................... 38
10.3. Statistical Analyses ...................................................................................................... 38
10.3.1. Safety Analyses ................................................................ .................................... 38
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 38
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 39
10.3.2. Pharmacokinet ic Analyses .................................................................................... 39
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 39
[IP_ADDRESS]. Pharmacokinet ic Statistical Inference ............................................................. 39
10.3.3. Cardi ovascular Analyses ...................................................................................... 39
[IP_ADDRESS]. Cardi ovascular Param eter Estimat ion............................................................. 39
[IP_ADDRESS]. Statistical Inference of Cardiovascular Parameters .......................................... 39
10.3.4. Biomarker Analyses ............................................................................................. 40
10.3.5. Interim Analyses .................................................................................................. 40
11. References ........................................................................................................................ 41
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178755] ives and Endpo ints....................................................................... 18
Table LAHU.2. Sequences in Study  LAHU ..................................................................... 19
Table LAHU.3. Treatments Administered ........................................................................ 26
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178756] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 42
Appendix 2. Clinical Laboratory  Tests ........................................................................ 46
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 47
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 50
Appendix 5. Blood Sam pling Summary ...................................................................... 51
Appendix 6. Protocol  Amendment H8H -MC-LAHU(c) Summary :  A 
Randomized, Double -Blind, Four -Period, Crossover Study  to 
Evaluate the Cardiovascular Effect of Single Oral Doses of 
Lasmiditan when Coadministered with Single Oral Doses of 
Sumatriptan in Hea lthy Subjects ............................................................. 52
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 7
LY5731441.Protocol Synopsis
Title of Study:
A Randomized, Double -Blind, Four -Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral 
Doses of Lasmiditan when Coadministered with Single Oral Doses of Sumatriptan in Healthy Subjects
Rationale: 
The study  will assess the cardiovascular effects of coad ministration of single doses of sumatriptan 100 mg and 
single doses of lasmiditan 200 mg as measured by [CONTACT_154514] 24 -hour ambulatory blood pressure (ABP) 
monitoring (ABPM) .  Pharmacokinetics (PK) , safety, and tolerability will also be reported.   Sumatriptan is known to 
cause a transient increase in blood pressure (BP) and is contra indicated in patients with moderate and severe 
hypertensio n and mild uncontrolled hypertension .  Initial studies with lasmiditan have identified mild effects on 
cardiovascular parameters (pulse rate [PR] and BP). In clinical practice, lasmiditan may be co administered with 
sumatriptan.  Therefore, Study H8H-MC -LAHU is being conducted to evaluate the cardiovascular effects and PK 
impact of coadministration of lasmiditan with sumatriptan in healthy subjects.
Objectives /Endpoints:
Objectives Endpoints
Primary
To compare and contrast the cardiovascular effects of 
lasmiditan 200 mg and sumatriptan 100 mg administered 
together to the cardiovascular effects of single doses of 
either drug administered alone.Systolic BP(SBP), diastolic BP(DBP), mean arterial 
pressure (MAP), and PRper 24 -hour ABPM .
Secondary
To evaluate PKof lasmiditan 200 mg and 
sumatriptan 100mg administered either alone 
ortogether.
To evaluate the safety and tolerability of 
lasmiditan 200 mg and sumatriptan 100 mg.Maximum observed drug concentration (C max), 
time of maximum observed drug concentration 
(tmax),area under the concentration versus time 
curve (AUC) from time 0 extrapolated to 
infinity  (AUC) [0-∞]), and AUC from time [ADDRESS_178757] time point with a 
measurable concentration (AUC[[ADDRESS_178758]]).
A summary of the number of 
treatment -emergent adverse events (TEAEs) 
and serious adverse events (SAEs).
Summary of Study Design :
Study H8H-MC -LAHU is a randomized, double -blind (subject -and investigator -blinded) , crossover study with 
4study periods in healthy  subjects to investigate the cardiovascular effects , PK, and safety and tolerability of oral 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 8
LY573144doses of lasmiditan alone, sumatriptan alone , and sumatriptan in combination with lasmiditan .  All subjects will 
participate in 4 treatment periods.  The treatments are as follows:
Treatment A:  lasmiditan 200 mg + sumatriptan 100 mg
Treatment B:  lasmiditan 200 mg + placebo
Treatment C:  sumatriptan 100 mg + placebo
Treatment D:  placebo + placebo
Each subject will be randomized to one of 4treatment sequences in a William’s square design (i.e. ABC D, BCDA, 
CDAB, and DA BC).
Treatment Arms and Planned Duration for Individual Subjects:   
Screening Period:
All subjects will participate in a screening visit up to 28 days prior to Period 1 study drug dosing.
Treatment Periods:
All subjects will participate in 4 treatment periods.  Subjects will be randomized to 1of 4treatment sequences.  
They  will be admitted to the clinical research unit ( CRU )the day prior to dosing (Day -1)in Period 1 , and will be 
dosed on Day 1 of each treatment period according to their assigned treatment sequence. Subjects will be 
discharged from the CRU on Day 3 of Period 4, following the collection of all ABP measurements and 
pharmacokinetic (PK) blood samples .  There will be a washout of at least [ADDRESS_178759] 5days after discharge from Period 4 .
Number of Subjects :
Up to 40 subjects may be enrolled to ensure 3 0 subjects complete the study.
Statistical Analysis:
Cardiovascular parameters that will be assessed by [CONTACT_154515], DBP, and 
MAP, and nadir hourly mean value of PR.  The parameters will be listed, and summarized using descriptive 
statistics, as appropriate. Changes from baseline in cardiovascular parameters SBP, DBP, MAP, and PR will be 
analy zed to determine the impact of a sin gle dose of sumatriptan 100 mg o n the cardiovascular parameters of 
lasmiditan. A repeated measures linear mixed -effects model with baseline as a covariate, fixed effects for time 
point, treatment, period (1, 2, 3, or 4), treatment sequence and the treatme nt by  [CONTACT_101839], and a random 
effect for subject will be used. Least squares (LS) means and treatment differences ([lasmiditan + sumatriptan] -
[lasmiditan + placebo]) will be calculated and presented with the corresponding confidence interva ls (CIs). The 
same model will be used to assess the impact of a single dose of lasmiditan [ADDRESS_178760] of a single dose of sumatriptan 100 mg on the PK of lasmiditan and its metabolites .  Log -transformed C max
and AUC parameters will be evaluated using a linear effects model with fixed effects for treatment, period (1, 2, 3, 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 9
LY573144or 4),and treatment sequence, and a random effect for subject.  From this model, the 90% CIsof the ratios of 
geometric means from Treatmen t A(lasmiditan + sumatriptan) will be determined and presented versus those of 
Treatment B (lasmiditan +placebo) .  The  tmaxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the 
median difference based on the observed medians, 90% CIs, an d the p -value from the Wilcoxon test will be 
calculated.   The same model will be independ ently used to assess the impact of a single dose of lasmiditan 200 mg 
on the PK of sumatriptan.
Safety parameters that will be assessed include clinical laboratory parameters, vital signs, and 12 -lead 
electrocardiogram (ECG) parameters.  The parameters will be listed, and summarized using descriptive statistics, as 
appropriate.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 10
LY5731442.Schedule of A ctivities
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 11
LY573144Study Schedule Protocol H8H -MC-LAHU
Screening Periods 1, 2, 3, and 4 Early DiscontinuationFollow -
UpComments
Procedure-28 to -2 days 
prior to 
Day 1/Period 1Day -[ADDRESS_178761] in Period 1 only; 
subjects should remain 
inpatient until Day [ADDRESS_178762] 
AdministrationDay 1, 
indicates 
Time = 0Subjects will fast 8hours 
before and 3hours after 
study drug administration.
Medical History
X XAfter screening, medical 
history  should include 
interim medical history.
Concomitant 
MedicationX X X X X X X
Adverse Event 
ReviewX X X X X X X
Height X
Weight X
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 12
LY573144Screening Periods 1, 2, 3, and 4 Early DiscontinuationFollow -
upComments
Procedure-28 to -2 days 
prior to Day 
1/Period 1Day -[ADDRESS_178763]
5days 
after 
discharge 
from 
Period 4
Vital Signs (Supi[INVESTIGATOR_050])
X XPredose, 1 , 
2 and 4 h24 h XTime points may be added 
for each study period, if 
warranted and agreed upon 
between Lilly and the 
investigator.
ABPM X X The ABPM device will be 
worn for approximately 
2hours before dosing and 
will continue to be worn 
until the 24 -hour postdose 
assessment is complete .
ABPM Training X Subjects should be trained 
on the ABPM device on the 
evening of Day -1 in 
Period 1 only.  Data from 
this acclimation period will 
not be stored or analyzed.
Orthostatic Vital 
SignsX Time points may be added if 
warranted and agreed upon 
between Lilly and the 
investigator.
Clinical Lab Tests X X X X SeeAppendix 2 , Clinical 
Laborato ry Tests, for details.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 13
LY573144Screening Periods 1, 2, 3, and 4 Early Discontinuation Follow -up Comments
Procedure-28 to -2 days 
prior to Day 
1/Period 1Day -[ADDRESS_178764] will be performed at 
admission to Period 1and at 
follow -up.
12-Lead ECG X Predose 24 h X Single ECGs will be taken.
Physical Exam
X X X X XFull medical assessment 
(including neurological 
examination) will be 
performed at screening.  
After screening, m edical 
assessment only performed 
to include medical review 
and targeted examination, as 
appropriate.
Genetic Sample
XSingle sample for 
pharmacogenetic analysis 
taken prior to dosing on 
Day 1of Period 1.
Lasmiditan and 
Metabolite PK 
SamplesPredose, 
0.5, 1, 1.5, 
2, 2.5, 3, 4, 
6, 8, 12 h24and
36 h48 hSampling times are relative 
to the time of study 
treatment administration 
(0min).
Sumatriptan PK 
SamplesPredose, 
0.5, 1, 1.5, 
2, 2.5, 3, 4, 
6, 8, 12 h24 hSampling times are relative 
to the time of study 
treatment administration 
(0min).
H8H- MC- LAHU(c )  C l in ica l  Pha rmaco logy  P ro toco l Page  14
LY573144S c r e en in g P e r i od s  1 ,  2 ,  3 ,  and  4 E a r l y  D i s c on t inu a t i on F o l l ow- up C omm en t s
P r o c edu r e- 2 8  t o  - 2  d a y s  
p r i o r  t o  D a y 
1 /P e r i o d1D a y - 1 D a y 1 D a y 2 D a y 3A t  l e a s t
5d ay s  a f t e r  
d i s c h a r g e  
f r om  
P e r i o d  4
U ri n e  S am p l ef o r  
C rC l0 - 6 ,  6 - 1 2 ,  
and  
1 2 - 1 8h1 8 - 2 4 ,  
2 4 - 3 0  a n d  
3 0 - 3 6h3 6 - 4 2  
and  
4 2 - 4 8hU ri n e  c o l l e c t i o n  f o r  t h e  
d e t e rm i n a t i o n  o f  C rC l .
R e n a l  B i om a r k e r  
S am p l e sP r e d o s e ,  
0 . 5 ,  1 ,  1 . 5 ,  
2 ,  2 . 5 ,  3 ,  4 ,  
6 ,  8 ,  1 2h2 4a n d
3 6h4 8  hS am p l i n g  t im e s  a r e  r e l a t i v e  
t o  t h e  t im e  o f  s t u d y  
t r e a tm e n ta dm i n i s t r a t i o n  
( 0m i n ) .
A b b r e v i a t i o n s :   ABPM  =  am b u l a t o r y  b l o o d  p r e s s u r e  m o n i t o r i n g ;  C rC l  =  c r e a t i n i n e  c l e a r a n c e ;  CRU  =  c l i n i c a l  r e s e a r c h  u n i t;  ECG  =  e l e c t r o c a r d i o g r am ;  h=h o u r s ;  
m i n=m i n u t e s ;  PK  =  p h a rm a c o k i n e t i c s .  
N o t e :   i f  m u l t i p l e  p r o c e d u r e s  t a k e  p l a c e  a t  t h e  s am e  t im e  p o i n t ,  t h e  f o l l ow i n g  o r d e r  o f  t h e  p r o c e d u r e  s h o u l d  b e  u s e d :  ECG ,v i t a l  s i g n s ,  a n d  v e n i p u n c t u r e .W he r e  
v e n i p u n c t u r e  a n d  o t h e r  p r o c e d u r e s  t a k e  p l a c e  a t  t h e  s am e  t im e  p o i n t ,  t h e  f o l l ow i n g  t im e  w i n d ow s  f o r  o b t a i n i n g  b l o o d  s am p l e ss h o u l d  b e  m a i n t a i n e d :  
>0to2h o u r s  p o s t d o s e :  ±5  m i n u t e s ;  2 . 5t o  6  h o u r s  p o s t d o s e :  ± 1 0  m i n u t e s ;  7  t o  1 2  h o u r s  p o s t d o s e :  ±2 0  m i n u t e s ;  > 1 2  h o u r s  p o s t d o s e :± 3 0  m i n u t e s .  W h e r e  
r e p e a t s  o f  sup in e  v i t a l  s i g n s  m e a s u r em e n t s  a r e  r e q u i r e d ,  r e p e a t s  s h o u l d  b e  p e r f o rm e d  a f t e r  v e n i p u n c t u r e .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 15
LY5731443.Introduction
3.1. Study Rationale
Lasmiditan is a small mo lecule serotonin (5 -hydroxytryptamine; 5-HT)1Freceptor agonist being 
developed for the acute treatment of migraine.   Triptans, which are [ADDRESS_178765] at the 5 -HT 1Freceptor with >4 50-fold higher affinit y for the 5 -HT 1Freceptor than for 
5-HT 1B and 5 -HT 1Dreceptors (Capi [CONTACT_2297]. 2017) .  Lasmiditan is under development as a neurally 
acting treatment for migraine wit hout the vasoconstrictor liabilit y of tri ptans.
Sumatriptan is a synthetic triptan used for the treatment of migraine and cluster headaches , 
known to cause a transient increase in blood pressure (BP) ,and is contraindicated in patients 
with moderate and severe hypertensio n, and mild uncontrolled hypertension .
Sumatriptan has an oral bioavailabilit y of approximately 15%, partially  attributable to the 
presystemic metabo lism of sumatri ptan via monoamine oxidase (MAO) .  Due to the 
predominance of this metabo lism pathway, the potent ial for MAO inhibitors to cause clinically  
signifi cant drug -drug interactions is high.  In vitro studies suggest that lasmiditan is not a 
monoamine oxidase inhibitor ,and it is expected that the likelihood of lasmiditan affect ing 
sumatri ptan pharm acokinetics ( PK)is low.  In clinical practice, lasmiditan may be 
coadministered with sumatri ptan; it is therefore perti nent to determine the potential for 
pharmacodynamic (PD) or PKdrug interactions .This study  will assess the effect of single doses 
of sumatri ptan 100 mg on the cardi ovascular effects of single d
oses of lasmiditan 200 mg;the 
effect of single doses of lasmiditan 200 mg on the cardiovascular parameters of sumatriptan , and 
the cardiovascular effects of either drug alone , as measured by [CONTACT_154514] 24- hour 
ambulatory  blood pressure (ABP) m onitoring (ABPM) .  Pharmacokinet ics, safety and 
tolerabilit y will  also be reported.
3.2. Background
Two Phase [ADDRESS_178766] been co mpleted wi th lasmidi tan in the acute treatm ent of migraine, 
using doses of up to 45 mg over 20 minutes of the intravenous ( IV)formulation(Study  COL 
MIG -201) , and up to 400 mg of the oral tablet formulat ion(COL MIG -202) .  One Phase 3 
randomized, double -blind, placebo -controlled trial has been completed in the [LOCATION_002] 
(COL MIG -301 [SAMURAI]), where 1856 patients were randomized to 100mg lasmidi tan 
(630 subjects), 200 mg (609 subjects), or placebo (617 subjects), respectively. In the SAMURAI 
study , both [ADDRESS_178767] bothersome migraine symptoms (nausea, phonophobia, and 
photophobi a) com pared to pl acebo.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178768] been completed and methods of administration included 
IV, oral, and sublingual.  Lasmiditan was tolerated by  [CONTACT_154516] 180 mg over 20 or 60minutes (H8H- BD-LACA; 40 subjects), as a solution formulation 
administered orally or sublingually up to doses of 400 and 32 mg, respectively (COL MIG -102; 
60subjects), as oral tablets or a solution formulat ion up to dos es of 400 and 200 mg, respectively 
(COL MIG -103; 44 subjects), and as oral tablets of200mg (COL MIG -104; 30 subjects) and up 
to 400mg (COL MIG -105; 55 subjects).
Across the completed Phase 1, 2, and 3 clinical studies, doses of 0.1 mg to 400 mg o f lasmiditan 
were evaluated in healt hy subjects or patients with migraine ; methods of administration included 
IV, oral, and sublingual .  Com pared wi th placebo, the most frequent ly reported lasmiditan 
treatm ent-emergent adverse events (TEAEs) across all studies included so mnolence, fat igue, 
dizziness, paresthesia, and hot flashes.  The majority  of these TEAEs were mild or moderate in 
severit y and none l ed to subject withdrawal.  One patient in the Phase 2 dose -ranging study  in 
migraineurs experi enced a seri ous adve rse event (SAE) of di zziness that was moderate in 
severit y, occurred approximately [ADDRESS_178769] dose of 180 mg (H8H -MC-LACA), lasmidi tan produced a 
statist ically significant but small dose -related decrease in pulse rate ( PR)and increase in BP, 
although the m agnitude of  these effects was considered unlikely to be of clinical significance in 
this group of healt hy subjects .  Foll owing oral  administrati on at doses of up to 400 mg
(COL MIG -102) , PRagain was slight ly reduced, but there were no consistent effects on BP.  The 
effects on vital signs were t ransient, not dose -related, and unlikely to be clinically significant 
given the intended intermitten 7t use of  lasmidi tan.
Oral tablet doses of lasmiditan up to 400 mg (COL MIG -103) did not result in any clinically 
relevant changes in electrocardiograms (EC Gs) (incl uding QT interval/corrected QT interval 
[QTc]) fo llowing administration to healthy  subjects.  In the thorough QT study  (COL MIG -105) 
in healthy subjects, no clinically  significant changes in BP, PR, or 12 -lead ECG were observed at 
the 100 or 400 mg dose l evels.  Lasmiditan caused no significant QT prolongat ion at ei ther dose.
In healthy subjects, peak plasma concentrations of lasmiditan were observed approximately 1 to 
2.5 hours after a single oral dose ranging fro m 25 to 400 m g, and the geometric mean terminal 
half-life was approximately 4 to 6 hours.  Lasmidit an exhibited dose -linear PK; low to moderate 
inter-subject variabilit y in exposure was observed across doses ( coefficient of variat ion [%CV
]
up to 61% and 45% for maximum observed drug concentration [Cmax] and area under the curve 
[AUC], respectively ; COL MIG -102).  Co-administration of lasmiditan wit h a high fat diet 
(COL MIG -104) led to a delay in median time o f maximum observed drug concentration (t max) 
value by  [CONTACT_3450]  1hour and a modest (~20%) increase in lasmiditan C maxand AUC 
values, relative to that under fasted condit ions.   
Following exploratory  analysis of human plasma samples from adult subjects receiving oral 
lasmidit an, 3majo r human metabolit es (M7, M8, and [S,R] -M18) were observed.  Ketoreduction 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 17
LY573144of lasmidi tan to M8 (al coho l) appears to be the major metabo lic pathway, presumably vianon-
CYP enzymes.  In human liver microsomes, CYP1A2 and CYP3A4 appear to be invo lved to a 
minor extent in lasmi ditan metabolism .  Unchanged lasmiditan comprises approximately 2% of 
the dose excreted in urine.  Lasmiditan is a very weak inhibitor of CYP3A4, CYP2D6, and 
P-glycoprotein .
3.3. Benefit/Risk Assessment
The primary  object ive for this study  is to compare and con trast the cardi ovascular effects of 
lasmiditan and sumatri ptan, in relat ion to vital signs following a single oral  dose al one or when 
coadministered in healthy subjects.  There is no anticipated therapeutic benefit for the subjects.
Lasmiditan has been well tol erated by  [CONTACT_72132] [ADDRESS_178770] single oral dose given (400 mg).  
Sumatriptan is a m arketed drug and will be administered within the recommended dose regimen 
for clinical use (100 mg).  Sumatriptan is known to cause transient increases in blood pressure at 
this dose.  This dose regimen has been tolerated in previous PK/PD studies in healt hy subjects 
(for example Nappi [CONTACT_2297]. 1994). Similar to the adverse events (AEs) observed fo llowing dosing 
with lasmidi tan, AEs observed fo llowing dosing wit h sumatriptan include, but are not limited to, 
fatigue, dizziness, paresthesia, and hot flashes.
Dosing o f lasmiditan and sumatriptan in this study  will be conducted in an inpat ient setting and 
subjects will be monitored in -house for at least [ADDRESS_178771] igator's brochure ( IB).
More detailed informat ion about the known and expected benefits and risks of sumatri ptan may 
be found in the fo llowing:  Patient Inform ation Leaflet or Summary o f Product Characterist ics.
H8H- MC- LAHU(c )  C l in ica l  Pha rmaco logy  P ro toco l Page  18
LY5731444 .Ob jec t ivesand  Endpo in ts
T a b l eLAHU.1s h ow s  t h e  o b j e c t i v e s  a n d  e n d p o i n t s  o f  th e  s tudy .
Tab leLAHU.1 . Ob jec t ives  and  Endpo in ts
Ob j e c t i v e s Endp o in t s
P r im a r y
T o  c om p a r e  a n d  c o n t r a s t  t h e  c a r d i o v a s c u l a r  e f f e c t so f  
l a sm i d i t a n  2 0 0m g  a n d  s um a t r i p t a n  1 0 0m g  a dm i n i s t e r e d  
t o g e t h e r  t o  t h e  c a r d i o v a s c u l a r  e f f e c t so f  s i n g l e  d o s e s  o f  
e i t h e r  d r u g  a dm i n i s t e r e d  a l o n e .Sys t o l i c  BP(SBP ) ,  d i a s t o l i c  BP(DBP ) ,  m e a n  a r t e r i a l  
p r e s s u r e  (MAP ) ,  a n d  PRp e r  2 4 - h o u r  ABPM.
S e c ond a r y
T o  e v a l u a t et h e  PKo f  l a sm i d i t a n  2 0 0m g  a n d  
s um a t r i p t a n  1 0 0m g  a dm i n i s t e r e d  e i t h e r  a l o n e  
o r t o g e t h e r .
T o  e v a l u a t e  t h e  s a f e t y  a n d  t o l e r a b i l i t y  o f  
l a sm i d i t a n  2 0 0m g  a n d  s um a t r i p t a n  1 0 0m g . Cm a x,  tm a x,a r e a  u n d e r  t h e  c o n c e n t r a t i o n  v e r s u s  
t im e  c u r v e  (AUC )  f r om  t im e  0  e x t r a p o l a t e d  t o  
in f in i ty  (AUC [ 0 - ∞ ] ),  a n d  AUCf r om  t im e  0  t o  
t im e  t ,  w h e r e  t  i s  t h e  l a s t  t im e  p o i n t  w i t h  a  
m e a s u r a b l e  c o n c e n t r a t i o n  (AUC [ 0- t l a s t ] ) .
 A  s umm a r y  o f  t h e  n um b e r  o f  TEAE sa n d  
SAE s.
E xp l o r a t o r y
T o  e v a l u a t et h e  e f f e c t  o f  l a sm i d i t a n  o n  r e n a l  f u n c t i o n  
b i om a r k e r s  i n  s e r um  a n d  u r i n e .
T o  e v a l u a t e  t h e  PK  o f  l a sm i d i t a n  m e t a b o l i t e s  a l o n e  a n d  
i n  c om b i n a t i o n  w i t h  s um a t r i p t a n  i n  h e a l t h y  s u b j e c t s .Cys t a t i n  C ,  c r e a t i n i n e , a n d  c r e a t i n i n ec l e a r a n c e
Cm a x,  tm a x,  AUC ( 0 - t l a s t )  a n d  AUC ( 0 - ∞) .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 19
LY5731445.Study  Design
5.1. OverallDesign
This is a rando mized, double -blind, crossover study with 4 study  periods in heal thy subjects.  All 
subjects will par ticipate in 4 treatment periods.  The treatments are as fo llows:
Treatment A:  lasmiditan 200 mg + sumatri ptan 1 00mg
Treatment B:  lasmiditan 200 mg + placebo
Treatment C:  sumatriptan 100 mg + placebo
Treatment D:  placebo + placebo
Each subject will be rando mized to one of 4treatment sequences in a William’s square design as 
outlined in Table LAHU .2.
Table LAHU.2
. Sequences in Study LAHU
Sequence Period 1 Period 2 Period 3 Period 4
1 Lasmiditan + 
sumatri ptanLasmiditan + 
placeboSumatriptan + 
placeboPlacebo + placebo
2 Lasmiditan + 
placeboSumatriptan + 
placeboPlacebo + placebo Lasmiditan + 
sumatri ptan
3 Sumatriptan + 
placeboPlacebo + placebo Lasmiditan + 
sumatri ptanLasmiditan + 
placebo
4 Placebo + placebo Lasmiditan + 
sumatri ptanLasmiditan + 
placeboSumatriptan + 
placebo
Screening Period:
All subjects will part icipate in a screening visit up to 28 days prior to Period 1 study drug dosing.
Treatment Periods:
All subjects will part icipate in 4 treatment periods.  Subjects will be rando mized to one of 
4treatm ent sequences.  They  will be admi tted to the clinical research unit ( CRU )the day  prior to 
dosing (Day -1)in Period 1, and will be dosed on Day 1 of each treatm ent peri od according to 
their assigned treatm ent sequence (Table LAHU .2).  Subj ects will be discharged from the CRU 
on Day 3of Period [ADDRESS_178772] 5 day s after discharge fro m Period 4.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178773] scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject.
5.4. Scientific Rationale for Study Design
A double -blind ( subject -and invest igator -blinded ), randomized
,and pl acebo -controlled design is 
being used to minimiz e bias on the primary  object ive of this study .  
The study  blind will be maintained by  [CONTACT_154517] a blindfo ld, or pl acement of the tablets in an 
amber vial to disguise their appearance ; the sumatriptan tablets to be used in this study  will be 
similar in shape and size to both lasmiditan and lasmiditan placebo (round and approximately 
10mm in diameter), therefore lasmiditan placebo will also be used as the placebo for 
sumatri ptan.
A crossover design improves the sensit ivity for detecting any  cardi ovascul arsignals by [CONTACT_154518] (as are described in Section 3.2).  Conducting the study  in healthy subjects mit igates 
the potenti al confounding effects of the disease state and conco mitant m edicat ions.
The washout period is at least [ADDRESS_178774] ion is
necessary  for ca pturi ng tem poral  changes in creat inine disposit ion. The inclusio n of serum 
cystati n C, which provides a more precise measure of glomerular fil tration rate ( GFR ), enables 
different iation between changes in creatinine transport versus change in renal funct ion.
5.5. Justification for Dose
The dose level o f 200mg lasmiditan has been well tolerated in previous studies of healt hy 
subjects.  This dose level is expected to be the highest recommended single dose for lasmiditan.
The dose of sumatr iptan (100 mg) is within the range used in clinical pract ice.  More detailed 
inform ation can be found in the Sumatriptan Package Insert .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178775] ing 
condi tions will  be docum ented.
Screening may occur up to 28 day sprior to enrollment (Day 1).  Subjects who are not enrolled 
within 28 days of screening may be subjected to an additional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or enrollment:
[1] are overtly healt hy males or females, a s determined by  [CONTACT_72134]  
[
1a]male subjects:
are not required to adhere to con tracepti ve requi rements.
[1
b]female subjects:
of childbearing potential, must test negative for pregnancy at screening, and 
agree to use a reliable method of birth control during the study and for 
1week fo llowing the l ast dose of l asmidi tan.  Reliable methods of 
contraception for female subjects of c
hildbearing potential include the use of 
stable horm onal contracepti on, bilateral  tubal  ligat ion, intrauterine device, or 
diaphragm  with spermicide alo ng with male partner’s use of male condom 
with spermicide.
of non-childbearing potential, i.e., postmeno pausal or permanent ly sterile 
following hysterectomy, bilateral salpi[INVESTIGATOR_1656], or confirmed tubal 
occlusion (not tubal  ligation), as determined by [CONTACT_9870] .  
Postmenopausal  is defined as spontaneous amenorrhea for at least 
12months, and a plasma fo llicle -stimulating hormone (FSH) level greater 
than 40 m IU/mL, unless the subject is taking hormone replacement therapy  
(HRT). 
[2] a re aged 18 to 65 y ears ol d, inclusive, at the time of screening.
[
3]have a body  mass index (BMI ) of 19.0 to 35.0 kg/m 2,inclusive , at screening.
[4] h ave clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th acceptabl e deviat ions that are 
judged to be not clinically significant by  [CONTACT_093]
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 22
LY573144[5] have venous access sufficient to allow for blood sampling as per the protocol.
[
6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures .
[7] have given written informed consent approv ed by  [CONTACT_105331] (ERB) governing the site.
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igativesite personnel  direct ly affiliated with this study and their 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling.
[9] are Lilly  or Covance empl oyees.
[10]are currently enrolled in a clinical  study  involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[
11] have known allergies to lasmiditan , sum atriptan, related compounds ,or any  
components of the formulat ions of lasmidi tanand sumatri ptan.
[12] are persons who have previously received the investigat ional product in this 
study , who have been wit hdrawn fro m this study , or who have received 
lasmiditan in any other study  invest igating lasmiditan within the 3 m onths 
prior to screening .
[13] have participated (dosed with any investigational product), within the [ADDRESS_178776] has a long half -life, 5 half-lives or 30 days
(whichever is longer) should have passed.
[14] have a history  of, or ECG findings of, clinically significant brady cardia, heart 
block, tachy  or brady  arrhy thmias, or have an y other abnormalit y in the 
12-lead ECG that, in the opi[INVESTIGATOR_3078] n of the invest igator, i ncreases the risks 
associ ated wi th parti cipat ing in the study .
[15] have a history , signs, or symptom s of arrhy thmia or Wolff Parkinson White
syndro me that could affect the subject’s safet y.
[16] have an est imated glomerular filtration rate (eGFR) of < 60mL/min/1.73 m2
as determined by  [CONTACT_91019] -EPI [INVESTIGATOR_154510]:
GFR = 141 × minimum(Scr/ ĸ, 1)α× maximum(Scr/ ĸ, 1)-1.209× 0.993Age× 
(1.018 if female) × (1.159 if black).
Scr is serum  creat inine; ĸ is 0.7 for f emales and 0.9 for males; 
αis -0.329 for females a nd -0.411 for m ales.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 23
LY573144Minimum indicates the minimum o f Scr/ĸ or 1; m aximum  indicates 
the maximum of Scr/or 1.
[17] have a rest ing SBP >135 mmHg and DBP >85 mmHg at screening .  
Additional assessment smay be performed to confirm  eligibilit y.
[
18] have a histo ry of syncope, presyncope, uncontrolled vertigo, postural 
dizziness, or being at risk for falls, as judged to be clinically significant by  [CONTACT_1275], or have orthostatic decreases in SBP of >[ADDRESS_178777] 
orthostati c decreases in DBP of >10 mmHg at screening.  May  be repeated on 
1 occasion if asymptomat ic.
[19] have a supi[INVESTIGATOR_154511] <50 or >90 bpm  at screening.   Additional assessments 
may be performed to confirm eligibilit y.
[20] ha ve significant history  of or current card iovascular, respi[INVESTIGATOR_696] (including 
bronchospasm or bronchial asthma, or chronic obstructive airways disease) , 
hepat ic, renal, gastrointest inal, endocrine, hematological, or neurological 
disorder , or a condition capable of significant ly alt ering the absorption, 
metabo lism, or eli minat ion of drugs; of const ituting a ri sk when taking the 
study  medicat ion; or of interfering with the interpretation of data .  
Appendectomy, splenectomy, and cholecystectomy  are considered as 
acceptable.
[
21] have a history , signs, or symptom s of vas ospas tic coronary  artery  disease .
[22] a history  of allergic react ions to medicat ions or food products.
[23] have known or ongoing neuropsy chiatri c disorders (for example, manic 
depressive illness, schizophrenia, depressio n)considered as clinically 
significant by [CONTACT_24342] .
[24] show a history  of central  nervous sy stem  (CNS) condit ions such as strokes, 
transi ent ischemic attacks, si gnificant head traum a, seizures, CNS infect ions, 
migraines, brain surgery  or any  other neurol ogical  condi tions that, in the 
opi[INVESTIGATOR_3078] n of the Invest igator, increase the risk of parti cipat ing in the study .
[25] have a clinically  significant abnorm ality in the neurol ogical  examinat ion.
[26] have a history , signs, or symptom s of Raynaud ’s pheno menon, hypertension, 
ischemic bowel dise ase, or peripheral vascular disease.
[
27] have an average weekly  alcohol  intake that exceeds 21 units per week (males 
up to age 65), and 14 units per week (females), or are unwilling to stop 
alcoho l consumpt ion [ADDRESS_178778] agree to consume no 
more than 2 units per day (1unit = 12 oz or 3 60 mL of beer ; 5oz or 150 mL 
of wine; 1.5 oz or 45 mL o f distilled spi[INVESTIGATOR_2120]).
[
28] currently use, or within the past [ADDRESS_178779] 6 months based on history  
at the screening visit .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 24
LY573144[29] are unwilling to refrain fro m tobacco -or nicotine -containing products from 
3months pri or to screening unt il discha rge from the study .
[30] have received centrally  active drugs or th ose affecting peripheral cho linergic 
transmissio n within the 3 months prior to Day -1.
[31]
use of monoamine oxidase -A inhibitors and other drugs associated with 
serotonin syndro me(i.e. se lective serotonin reuptake inhibitors ,selective 
serotonin -norepi[INVESTIGATOR_5608] , tricyclic ant idepressants, and 
5-HT1 agonists )within the [ADDRESS_178780] dosing occasi on.
[32]
intend to use over -the-counter or prescript ion medication, including dietary  
supplements, within 14 days pri or to d osing and until study  discharge (apart 
from occasi onal acetaminophen, horm onal contracepti on, or HRT) .
[
33] s how evidence of human immunodeficiency  virus (HIV) infection and/or 
positive human HIV ant ibodies .
[34]
show evidence of hepatit is C and/or positive hepat itis C ant ibody .
[35]
show evidence of hepatit is B and/or positive hepat itis B surface antigen .
[36]
are wom en with a posi tive pregnancy test or who are lactating .
[37]
have donated b lood of  more than 500 mL within 1 month prior to the 
screening visit.
[38] in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, are unsuitable for inclusio n in 
the study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [1] through [7] define a healt hy population suitable for evaluat ion in a Phase 1 study.  
Criteria [8] and [9] prevent conflict of interest in study  parti cipants.  Cri teria [10] through [ 38] 
predominant ly exclude medical condit ions, m edicati on intol erance, and concomitant medicat ion 
usethat may confound the assessment of study  endpoints.
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , 
subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Lasmiditan and sumatriptan will be administered after an overnight fast of at least 8 hours.  On 
Day 1 of each treatm ent peri od, subjects will abstain from water 1 hour before and after dosing 
(except for water given with the dose).  Subjects will remain fast ing for approximately 3 hours 
postdose, at which time a meal will be served.
6.3.2. Caffeine, Alcohol, and Tobacco
Caffeine –Subjects will refrain fro m consuming xanthine -or caffeine -containing food and 
drinks fro m 48 hours prior to admissio n in Peri od 1, and whil stresident at the CRU.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 25
LY573144Alcohol –Subjects will not consume alcoho l for [ADDRESS_178781] consume no more than 2 units per 
day (1 uni t = 12 oz or 360mL of beer; 5 oz or 150 mL o f wine; 1.[ADDRESS_178782] illed 
spi[INVESTIGATOR_2120]).
Tobacco –Subjects will refrain fro m smoking from 3 mo nths prior to screening until discharge 
from the study .  
Grapef ruit–Subjects will refrain fro m consuming grapefruit and grapefruit -containing products 
from 7 days pri or to Day  1 in Period 1, and until study discharge.
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to a dmissio n in each treatment period 
until after the fo llow-up visi t.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen fa ilure) m ay not be 
re-screened . 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178783] igational products used in this study  are shown in Table LAHU .3.
Tablets of lasmiditan and sumatriptan will be administered orally wit h approximately 240 mL o f 
room  temperature water, in a sitting posit ion.  Tablets of lasmiditan and sumatriptan will be
administered in the morning of Day 1 of each treatment period.  Subjects will not be allowed to 
lie supi[INVESTIGATOR_2525] 2 hours after dosing, unless clinically indicated or for study procedures.
Table LAHU.3
. Treatment sAdministered
Treatment Name [CONTACT_154524] (lasmiditan)
Dosage Formulation film-coated tablet film-coated tablet film-coated tablet
Unit Dose 
Strength/Dosage Level(1 200-mg) tablets/
200 mg lasmiditan(1 100-mg) tablets/ 
100mg sumatriptan--
Route of Administration Oral Oral Oral
Dosing Instructions [ADDRESS_178784] igator or designee is responsible for:
explaining the correct use of the investigational product (s) to the site personnel 
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
and returning all unused medicat ion to L illy or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Each tablet of lasmiditan contains 200mg of act ive ingredient and is provided as bulk suppl iesin 
bottles.  Sumatriptan will be sourced by  [CONTACT_72137].
Both l asmidi tan and sumatri ptan tablets a re round and [ADDRESS_178785] will be labeled according to the country’s regulatory  requi rements.
7.2. Method of Treatment Assignment
All subjects will par ticipate in 4 treatm ent peri ods.  The treatments are as fo llows:
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 27
LY573144Treatment A:  lasmiditan 200 mg + sumatri ptan 100 mg
Treatment B:  lasmiditan 200 mg + placebo
Treatment C:  sumatriptan 100 mg + placebo
Treatment D:  placebo + placebo
Each subject will be rando mized to one of 4treatment sequences in a William’s square design 
(i.e.,ABC D, BCD A, CD AB, and DAB C) using a com puter -generated allocation schedule .
7.2.1. Timing of Doses
The doses will be administered at approximately the same t ime on Day [ADDRESS_178786]’s electroni c 
case report form  (eCRF).
7.3. Blinding
Each subj ect will either be blindfo lded at each dosing occasion , or will receive the study  drug in 
an amber vial, to maintain the study  blind.  Blinding will also be maintained throughout the 
conduct of the study  as described in the separate Blinding Plan.
Emergency  codes will be available to the invest igator .  A code, which reveals the treatm ent 
sequence for a specific study  subject, m ay be opened during the study only if the subject’s 
well-being requires knowledge of the subject’s treatment assignment.
If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician (CRP) for the study  parti cipant to c ontinue in the study .  During the 
study , emergency  unblinding shoul d occur only by [CONTACT_154519]’s em ergency 
code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent as signment i s warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investigato r to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible .
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study .
7.5. Preparation /Handling/Storage/Accountability
The invest igator or designee must confirm all investigat ional product was received in good 
condi tion, and any  discrepancies are reported and resolved before use of the study  treatm ent.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178787] should be stored in a nenvironm entally  controlled and mo nitored (m anual  
or automated) area in accordance wit h the labeled storage condit ions wit h access limited to the 
investigator and authorized site staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
The invest igational product will be administered at the clin ical site, and documentation of 
treatm ent administration will occur at the site.
7.7. Concomitant Therapy
In general, concomitant m edicat ion shoul d be avoided; however, acetaminophen (maximum 
2g/24 hours) may be administered at the discretion of the invest igator for treatment of headaches 
etc.  Contraceptive medicat ion is permitted as per the inclusio n criteria.  Horm one replac ement 
therapy  is also allowed.
If the need for concomitant medicat ion (other than acetaminophen , horm onal contracepti on,or 
HRT) ari ses, inclusio n or continuat ion of the subject may be at the discretion of the invest igator 
after consul tation wi th a Lilly clinical pharmaco logist, CRP , or designee .  Any medicat ion used 
during the course of the study  must be docum ented.
7.8. Treatm ent A fter the End of the Study
Not applicable.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178788] meets 1 of the f ollowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
alanine aminotransferase ( ALT ),aspartate aminotransferase ( AST) >5X upper limit of 
norm al(ULN)
ALT or AST >3X ULN and total bilirubin >2X ULN orinternat ional norm alized rati o
(INR)>1.5
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosph atase (ALP ) >3X ULN
ALP>2.5X ULN and total bilirubin >2X ULN
ALP>2.5X ULN wi th the appearance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist/CRP or 
designee and the invest igator to determine if the subject may continue in the study .  If both agree 
it is medically appropriate to continue, the invest igator m ust obtain documented approval from 
the Lilly clinical pharmaco logist/CRP or desi gnee to allow the inadvertently enrolled subject to 
continue in the study  with or wi thout continued treatment with invest igational product.   
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other type of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator decision
othe invest igator decides that the subject should be discontinued from the study
Subject d
ecision
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178789] subjects who fail to return for a scheduled visit or were otherwise unabl e to be 
followed up by  [CONTACT_4179].
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178790] ivities, detailing the study  procedures and their timing 
(including tol erance limit s for timing).
Appendix [ADDRESS_178791] igator.
After the informed consent form ( ICF) is signed, s tudy site personnel  will record ,via eCRF ,the 
occurrence and nature of each subject ’s preexist ing conditions, including clinically significant 
signs and symptoms.   Addit ionally, site personnel will  record any  change in the condi tion(s) and 
the occurrence and nature of any AEs.  
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment or a study  procedure, taking into account co ncomitant 
treatm ent or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the invest igational product, study  device and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 32
LY5731449.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in de ath 
or hospi[INVESTIGATOR_313] m ay jeopardi zethe subject or may requi re interventi on to prevent 
one of the other outcomes listed in the definit ion above.
Study  site personnel  must al ert the Lilly  clinical pharm acologist/CRP , or its desi gnee, of any  
SAE as soo n as pract ically possible.
All AEs occurring after signing the ICF are recorded in the case report forms and assessed for 
serious cri teria.  The SAE reporting to the sponsor begins after the subject has signed the ICF 
and has received invest igational product.  However, if an SAE occurs after signing the ICF, but 
prior to receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines (see Sect ion9.2) if it is considered reasonably possibly 
related to study  procedure.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin [ADDRESS_178792] 
discontinued from and/or com pleted the study  (the subject summary eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, incl uding a death, at any  time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnanc y (maternal or paternal  exposure to investigat ional product ) does not meet the definit ion 
of an adverse event.  However, to fulfill regulatory requirements any pregnancy  should be 
reported fo llowing the SAE process to collect data on the outcome for both m other and fetus.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator reports as related to invest igational product or procedure. Lilly 
has procedures that will be fo llowed for the recording and expedited reporting of S[LOCATION_003]Rs that 
are consistent with global regulations and the associated detailed guidances.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178793] , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur
after the subject receives the first dose of invest igational product should be reported to Lilly  or 
its designee as an AE via eCRF.
9.4.2. Vital Signs
[IP_ADDRESS]. Supi[INVESTIGATOR_154512] , supi[INVESTIGATOR_154513] (Secti on
 2).  
Blood pressure and PRshoul dbe measured singly after at l east 5minutes supi[INVESTIGATOR_050] .  For each 
individual subject ,the sam e cuff size should be used throughout the study  for the m easurements 
of BP.  The cuff should be attached to the subject’s dominant arm.
Where orthostati c measurements are required, subjects should be supi[INVESTIGATOR_1919] 5 minutes 
and then subjects will stand, and standing blood pressure will be measured after 2 minutes; no 
longer than [ADDRESS_178794] feels unable to stand, supi[INVESTIGATOR_72125]. 
Unscheduled orthostatic vital signs should be assessed, if possible, durin g any  AE of dizziness or 
posture -induced symptoms.  
Addit ional vital signs may be m easured during each treatm entperiod if warranted .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178795] , ABPM will be performed according to the Schedule of Activit ies (Section 2).
Site invest igative personnel shoul d be trained on the correct posit ioning of the ABPM monitor, 
use of correct cuff size, and mo nitor calibration prior to the start of the study .  Subjects should be
trained on the ABPM device before the predose measurement in the first treatment period to 
maximize the collection of valid measurements, and to alleviate any  concerns about 
inconvenience due to the continuous [ADDRESS_178796]’s nondo minant arm and will record 
ambulatory  BP and PR every  20minutes during awake hours (for example, 0700 hours to 
2200 hours) and every 30 minutes throughout the night (2200 hours to 0700 hours).  On Day  [ADDRESS_178797] , 
single 12 -lead digital safet y ECGs should be co llected according to the 
Schedule of Activities (Secti on 2) .  Electrocardi ogram s may  be obtained at addit ional times, 
when deemed clinically  necessary .
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the invest igational, should be reported to Lilly, or its designee, 
as an AE via eCRF.
Electrocardiograms must be recorded before collecting any blood samples.  Subjects must be 
supi[INVESTIGATOR_1919] [ADDRESS_178798] ion.  All ECGs should be stored at the investigat ional site.
Electrocardiograms will be interpreted by  
a qualified physician ( the investigator or qualified 
designee) at the si te as soon after the time of ECG collect ion as possible, and ideally whil stthe 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically re levant findings be 
ident ified.
If a clinically significa nt quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the subject for symptoms (for example, palpi[INVESTIGATOR_814], near 
syncope, syncope) to determine whether the subject can continue in the study.  The in vestigator 
or qualified designee is responsible for determining if any change in subject management is 
needed and must document his/her review of the ECG printed at the time of evaluat ion from at 
least 1of the replicate ECGs fro m each time po int.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178799] or CRP /scientist will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly clinical 
pharmaco logist or CRP will periodically review the following data:
trends in safety  data
laboratory  analy tes 
AEs
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Pat ient Safety  therapeut ic area physician or clinical research scien tist.
[IP_ADDRESS]. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated total  
bilirubin ≥2X ULN, liver tests ( Appendix 4 ) should be repeated within [ADDRESS_178800] bili rubin , gamma- glutamyl  transferase ( GGT ),and 
creatinine kinase to confirm  the abnorm ality and to de termine if it is increasing or decreasing.  If 
the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_154520] .  Moni toring 
shoul d cont inue until levels normalize and/or are return ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5XULN on 2or more consecutive blood tests
elevated serum total bilirubin to ≥2XULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALP to ≥2XULN on 2or more consecutive blood tests 
subject discontinued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepatic event conside red to be a nSAE.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous bloo dsamples o f 
approximately  2mL each will be co llected to determine the plasma concentrations of lasmidi tan, 
and its metabolites, and [ADDRESS_178801] ion and handling of blood sam ples will  be provi ded by [CONTACT_456] .  
The actual  date and time (24-hour clock time) of each sampling will be recorded.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 36
LY5731449.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_97280].
Concentrations of lasmidi tanand its metabo lites will be assayed using a validated liquid 
chromatography  with tandem  mass spectrom etric detection (LC -MS/MS) method.  
Concentrations of sumatriptan will be assayed using a validated LC -MS/MS m ethod .
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f [ADDRESS_178802] visit for the study .  During this time, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism and/or protein binding work.
9.6. Pharmacodynamic s
Not applicable.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities, where l ocal regulati ons all ow.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
lasmiditan and to invest igate genet ic variants thought to play a role in migraine .  Asses sment of 
variable response may include evaluation of AEs or differences in efficacy .  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by [CONTACT_47550] .  
Samples will be retained for a maximum o f [ADDRESS_178803] visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
selected by [CONTACT_47551] i ts desi gnee .  This retenti on peri od enable s use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of lasmiditan or after lasmidi tanis commercially available.  
Molecular techno logies are expected to improve during the 15- year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
Regardless of te chno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarker s
9.8.1. Creatinine Clearance
Urine sample s(relative to the dosing time o f lasmidi tan) will be collected according to the 
Schedule of Act ivities (Section 2) to determine creatinine clearance . Thecollect ion will start at 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 37
LY573144the time o f dosing on Day  1andwill be completed on Day  3of each treatm ent peri od.  The 
actual vo lume of urine co llected and the time of ea ch co llection will be recorded.
Creatinine urine samples, together wi th the serum  creatinine measurement s, will be used to 
assess creat inine clearance .
The sample(s) will be stored per inst itutional standards at a facilit y selected by  [CONTACT_456].   
During this t ime, remaining samples may  be used for exploratory  analyses .
9.8.2. Renal Biomarker Samples
Analysis will be performed on renal funct ion bio markers, including, but not limited to, creatinine 
and cystatin C, to evaluate any  changes from  baseline (predose) following lasmiditan dosing.  
Venous blood samples will be collected as specified in the Schedule of Activit ies (Secti on2) for 
determinat ion of serum concentrations o f creatinine and cystatin C.
The samples will be ident ified by [CONTACT_154521] a maximum o f 2yearsafter the 
last subject visit for the study .
9.9. Health Economics
Thissection is not applicable for this study.
H8H- MC- LAHU(c )  C l in ica l  Pha rmaco logy  P ro toco l Page  38
LY57314410 .S ta t is t ica l  Cons ide ra t ions  and  Da ta  Ana lys is
10 .1 .Samp le  S izeDe te rm ina t ion
U p  t o  4 0  s u b j e c t s  m a y  b e  e n r ol l e d  t o  e n s u r e  3 0  s u b j e c t s  c om p l e t e  t h e  s t u d y .A s s um i n g  s t a n d a r d  
d e v i a ti o n  f o r  t h e  c h a n g e ,  w i t h i n - s u b j e c t ,  i n  SBPo f  1 2 . 7  mmH g  ( b a s e d  o n  r e s u l t s  f r om  s tudy  
) ,  t h i s  w i l l  r e s u l t  i n  a  9 0%  p r o b a b i l i t y  th a t  th e  h a l f - w i d t h  o f  t h e  9 0%  c o n f i d e n c e  
i n t e rv a l  (C I )  a b o u t  t h e  m e a n  w i t h i n - sub j e c t  ch ang e  b e tw e e n  p e r i o d s  i s  n o  l a r g e r  t h a n  4 . 6  mmH g .
10 .2 .Popu la t ions  fo r  Ana lyses
10 .2 .1 .S tudy  Pa r t ic ipan t  D ispos i t ion
A  d e t a i l e d  d e s c r i p t i o n  of  sub j e c t  d i s p o s i ti o n  w i l l  b e  p r o v i d e da t  th e  end  o f  th e  s tudy .  
10 .2 .2 .S tudy  Pa r t ic ipan t  Cha rac te r is t ics
T h e  s u b j e c t s ’  a g e ,  s e x ,  w e i g h t ,  h e ig h t ,  BM I ,  r a c e ,  a n d  o t h e r  d em o g r a p h i c  c h a r a c t e r i s ti c s  w i l l  b e  
r e c o r d e d  a n d  s umm a r i z e d  u s i n g  d e s c r i p t i v e  s t a t i s t i c s .
[ADDRESS_178804] e t e  d i s c l o s u r e s  o f  a n a l y s e s .  
10 .3 .1 .Sa fe ty  Ana lyses
10 .3 .1 .1 .C l in ica l  Eva lua t ion  o f  Sa fe tyCC I
A l l  i n v e s t i g a t i o n a l  p r o d u c ta n d  p r o t o c o l  p r o c e d u r e  AE s  w i l l  b e  l i s t e d ,  a n d  i f  t h e  f r e q u e n c y  of  
e v e n t s  a l l ow s ,  s a f e t y  d a t a  w i l l  b e  s umm a r i z e d  u s i n g  d e s c r i p ti v e  m e thodo l ogy .
T h e  i n c i d e n c e  o f  s ym p t om s  f o r  e a c h  t r e a tm e n t  w i l l  b e  p r e s e n t e d  b y s ev e r i ty  and  by  a s so c i a t i o n  
w ith  i n v e s t i g a t i o n a l  p r o d u c ta s  p e r c e i v e d  b y  t h e  i n v e s t i g a t o r .   S ym p t om s  r e p o r t e d  t o  o c c u r  p r i o r  
t o  e n r o l lm e n t  w i l l  b e  d i s t i n g u i s h e d  f r o m  th o s e  r e p o r t e d  a s  n ew  o r  i n c r e a s e d  i n  s e v e r i ty  d u r i n g  t h e  
s tudy .   E a ch  symp tom  w i l l  b e  c l a s s i f i e d  b y  t h e  m o s t  s u i t a b l e  t e rm  f r o m  th e  m ed i c a l  r e gu l a to ry  
d i c t i o n a ry .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178805] -related SAEs will be reported.
[IP_ADDRESS]. Statistical Evaluation of Safety
Clinical laboratory andvital signs param eters will  be listed and summarized using standard 
descript ive statistics.  Addit ional analysis will be performed if warranted upon review of the 
data.
10.3.2. Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic paramete r estimates for lasmiditan, its metabo lites, and sumatri ptan will be 
calculated by [CONTACT_154522].
The primary  parameters for analysis will be C max, tmax, AUC([ADDRESS_178806]), and AUC(0 -∞)of 
lasmiditan , its metabo lites,and sumatri ptan.  Other noncom partm ental  parameters, such as half -
life, apparent clearance, and apparent volume of distribut ion may be reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter estimates willbe evaluated to the impact of  a single dose of 
sumatri ptan 100 mg on the PK of lasmiditan and i ts metabo lites.  Log -transformed C maxand 
AUC param eters will be evaluated using a linear effects model wit h fixed effects for treatment, 
period (1, 2, 3, or 4) and treatment sequence , and a random effect for subject.  From this model, 
the 90% CIsof the rati os of  geom etric means fro m Treatment A (lasmidi tan+sumatri ptan) will 
be determined and presented versus those of Treatment B (lasmidi tan + pl acebo) .  
The tmaxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference 
based on the observed medians, 90% CIs, and the p- value fro m the Wilcoxon test will be 
calculated.   
The same model will be independent ly used to assess the impact of a single dose of lasmiditan 
200mg on the PK of sumatriptan.
Addit ional analyses m ay be performed, as warranted.
10.3.3. Cardiovascular Analyses
[IP_ADDRESS]. Cardiovascular Parameter Estimation
The primary  parameters for the cardi ovascular analyses will be peak hourly  mean values of SBP, 
DBP, and MAP, and nadir hourly  mean value of PR,and will be determined by [CONTACT_44117] .
[IP_ADDRESS]. Statistical Inference of Cardiovascular Parameters
Cardi ovascular param eters will  be listed, and summarized using descriptive statist ics, as 
appropr iate.  
Baseline value will be defined as the mean value during the 2hours pre -dose for each period.  
Changes fro m baseline in cardi ovascular param eters SBP, DBP, MAP, and PR will be analyzed 
to determine the impact of a single dose of sumatriptan 100 mg on the cardiovascular parameters
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 40
LY573144of lasmidi tan. A repeated measures linear mixed -effects m odel with baseline as a covariate, 
fixed effects for time point, treatment, period (1, 2, 3, or 4), treatment sequence ,and the 
treatm ent by  [CONTACT_101839], and a rando m effect for subject will be used. Least squares 
(LS) m eans and treatm ent differences ([lasmiditan + sumatriptan] -[lasmidi tan+placebo]) will 
be calculated and presented with the corresponding CIs. The same model will be used to assess 
the impact of a single dose of lasmiditan [ADDRESS_178807], CRP /investigator, or designee will consult with the 
appropriate medical director or designee to determine if it is necessary to amend the protocol.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 41
LY57314411. References
Capi M, de Andrés F, Li onetto L, Gentile G, Cipolla F, Negro A, Borro M, Martelletti P, 
Curto M.  Lasmiditan for the treatment of migraine.  Expert Opin Investig Drugs.   2017 
Feb;26(2):227 -234.
Nappi  G, Sicuteri  F, By[CONTACT_7943] M, Roncol ato M, Zerbini O. Oral sum atriptan com pared wi th placebo 
in the acute treatment of migraine. J Neurol . 1994;241(3):138- 144.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 42
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 43
LY573144Term Definition
5-HT 5-hydroxy tryptamine
ABP ambulatory blood pressure
ABPM ambulatory blood pressure monitoring
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine amino transferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve extrapolated from time 0 to infinity
AUC([ADDRESS_178808]) area under the concentration versus time curve from time [ADDRESS_178809] time 
point with a measurable concentration
blinding A procedure in which one or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect un til final 
database lock.
A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the subject is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the subje ctare not.  A double -blind study  is one in 
which neither the subject nor any of the investigator or sponsor staff who are involved in 
the treatment or clinical evaluation of the subjects are aware of the treatment received
BMI body mass index
BP blood p ressure
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178810] results meet the quality requirements defined 
by [CONTACT_57994].  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRP Clinical Research Physician :  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a p hysician, clinical research scientist, 
global safety physician or other medical officer.
CRU clinical research unit
DBP diastolic blood pressure
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acce ptable representatives.
ERB ethical review board
GCP good clinical practice
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICH International Co uncil forHarmoni sation
IND Investigational New Drug:  An application to the Food and Drug Administration to allow 
testing of a new drug in humans.
informed consent A process by [CONTACT_9444] a subject voluntarily confirms his or her willingness to participate in a 
particular study , after h aving been informed of all aspects of the study that are relevant to 
the subject ’sdecision to participate . Informed consent is documented by [CONTACT_3553] a 
written, signed and dated informed consent form .  
interim analysis An interim analysis is an analysi s of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
Investigational 
product Apharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study , including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or market ed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178811] ’sparticipation in the clinical study.
MAP mean arterial pressure
randomize the process of assigning subjects/ patients to an experimental group on a random basis
PK/PD pharmacokinetic/pharmacodynamic
PR pulse rate
SAE serious adverse event
SBP systolic blood pressure
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
tmax time of maximum observed drug concentration
ULN upper limit of normal
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 46
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Glucose (random)
Platelets Blood urea nitrogen
Differential WBC absolute counts and % of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin
Monocytes Alkaline phosphatase
Eosinophils Aspartate aminotransferase
Basophils Alanine am inotransferase
Creatinine
Urinaly sis Ethanol testinga
Specific gravity Urine drug screena
pH Hepatitis B surface antigen b
Protein Hepatitis C antibody b
Glucose HIV b
Ketones FSH c
Bilirubin
Urobilinogen
Blood
Nitrite
Urine microscopic (if positive result for blood)
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
WBC = white blood cells.
aUrine drug screen and ethanol level will be performed locally at screening and admission to the CRU, and may 
be repeated at other times indicated in the Schedule of Activities (Section 2).
bPerformed at screening only .
cPerformed at s creening only for confirmation of post -menopausal status.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178812] igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by [CONTACT_72140].  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational
product .
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  [CONTACT_72141] (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB
ICF
relevant curri cula vi tae
Regula tory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medica l Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 48
LY5731443)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signatur e page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
[CONTACT_47559], indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
Thesponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quali ty Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in conta ct with the study  site personnel by  [CONTACT_2319], 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47557]/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator wil l keep records of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the o riginal  source 
docum ents.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 49
LY573144Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  [CONTACT_456] .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with a pplicable laws, regulat ions, and GCP.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178813] Alkaline phosphatase isoenzymes a
GGT
CK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; C K = creatinine kinase; 
GGT =gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 51
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol H8H -MC -LAHU Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a 19.[ADDRESS_178814] 5 3 15
Lasmiditan and metabolite 
pharmacokinetic s2 56 112
Sumatriptan pharmacokinetic s 3 45 135
Renal biomarkers 2.5 56 140
Pharmacogenetics 10 1 10
Total 494
Total for clinical purposes (rounded up to the nearest 10 mL ) 500
aAdditional samples may be drawn if needed for safety purposes.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 52
LY573144Appendix 6. Protocol Amendment H8H -MC-LAHU(c) 
Summary :  A Randomized, Double -Blind, Four- Period, 
Crossover Study  to Evaluate the Cardiovascular Effect 
of Single Oral Doses of Lasmiditan when 
Coadministered with Single Oral Doses of Sumatriptan 
in Healthy  Subjects
Overview
Protocol  H8H -MC-LAHU , A Rando mized, Double -Blind, Four -Period, Crossover Study  to 
Evaluate the Cardi ovascular Effect of Single Oral Doses of Lasmiditan when Coadministered 
with Single Oral  Doses of Sumatri ptan in Heal thy Subjects ,has been amended.  The new 
protocol  is indicated by  [CONTACT_11827] ( c) and will be used to conduct the study  in place of any 
preceding versio n of the protocol.
Following feedback from the FDA from the Type C m eeting on 12 Octobe r 2017 , the protocol 
was amended to include an assessment on l asmidi tan metabo lites. In addit ion, language was 
added to clarify  the defini tions of  peak, nadir, and baseline for ABPM.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 53
LY573144Revised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
1. Protocol Synopsis
Statistical Analysis:
Cardiovascular parameters that will be assessed by [CONTACT_154515], DBP, and 
MAP, and nadir hourly mean value of PR.  The parameters will be listed, and summarized using descriptive 
statistics, as appropriate. Changes from baseline in cardiovascular parameters SBP, DBP, MAP, and PR will be 
analy zed to deter mine the impact of a single dose of sumatriptan 100 mg o n the cardiovascular parameters of 
lasmiditan. A repeated measures linear mixed -effects model with baseline as a covariate, fixed effects for time 
point, treatment, period (1, 2, 3, or 4), treatment sequence and the treatment by [CONTACT_101839], and a random 
effect for subject will be used. Least squares (LS) means and treatment differences ([lasmiditan + sumatriptan] -
[lasmiditan + placebo]) will be calculated and presented with the correspo nding confidence intervals (CIs). The 
same model will be used to assess the impact of a single dose of lasmiditan [ADDRESS_178815] of a single dose of sumatriptan 100 mg on the PK of lasmiditan and its metabolites .  Log -transformed C max
and AUC parameters will be evaluated using a linear effects model with fixed effects for treatment, period (1, 2, 3, 
or 4), and treatment sequence, and a random effect for subject.  From this model, the 90% CIsof the ratios of 
geometric means from Treatment A (lasmiditan + sumatriptan) will be determined and presented versus those of 
Treatment B (lasmiditan +placebo) .  The  tmaxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the 
median differ ence based on the observed medians, 90% CIs, and the p -value from the Wilcoxon test will be 
calculated.   The same model will be independently used to assess the impact of a single dose of lasmiditan 200 mg 
on the PK of sumatriptan.
Safety parameters that w ill be assessed include clinical laboratory parameters, vital signs, and 12 -lead 
electrocardiogram (ECG) parameters.  The parameters will be listed, and summarized using descriptive statistics, as 
appropriate.
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 54
LY573144Study Schedule Protocol H8H -MC-LAHU
Screening Periods 1, 2, 3, and 4Early 
DiscontinuationFollow -
UpComments
Procedure-28 to -2 days 
prior to 
Day 1/Period 1Day -[ADDRESS_178816]
5days 
after 
discharge 
from 
Period 4
Lasmiditan
and 
Metabolite
PK 
SamplesPredose, 
0.5, 1, 
1.5,2, 
2.5, 3, 
4, 6, 8, 
12 h24
and
36 h48 hSampling 
times are 
relative to the 
time of study 
treatment
administration 
(0min).
4. Objectives and Endpoints
Table LAHU. 1. Objectives and Endpoints
Exploratory
To evaluate the effect of lasmiditan on renal function 
biomarkers in serum and urine .
To evaluate the PKof lasmiditan metabolites alone and 
in combination with sumatriptan in healthy subjects.Cystatin C, creatinine, and creatinine clearance.
Cmax, tmax, AUC([ADDRESS_178817]) and AUC(0 -∞).
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  2mL each will be co llected to determine the plasma concentrations of lasmiditan
and its metabolites , and [ADDRESS_178818] ion and handling of blood samples w ill be provi ded by [CONTACT_456] .  
The actual  date and time (24-hour clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456] .
Concentrations of lasmiditan and its metabo lites will be assayed using a validated liquid 
chromatography  with tandem  mass spectrom etric detection (LC -MS/MS) method.  
Concentrations of sumatriptan will be assayed using a validated LC -MS/MS m ethod .
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page [ADDRESS_178819] visit for the study .  During this time, 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism and/or protein binding work.
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan , its metabo lites, and sumatri ptan will be 
calculated by [CONTACT_154523].
The primary  parameters for analysis will be C max, tmax, AUC([ADDRESS_178820]), and AUC(0 -∞) of 
lasmiditan , its metabo lites,and sumatri ptan.  Other noncom partm ental  parameters, such as half -
life, apparent clearance, and apparent volume of distribut ion may be reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter estimates will be evaluated to the impact of  a single dose of 
sumatri ptan 100 mg on the PK of lasmiditan and i ts metabo lites.  Log -transforme d C maxand 
AUC param eters will be evaluated using a linear effects model wit h fixed effects for treatment, 
period (1, 2, 3, or4) and treatment sequence , and a random effect for subject.  From this model, 
the 90% CIsof the rati os of  geom etric means fro m Treatment A (lasmidi tan+sumatri ptan) will 
be determined and presented versus those of Treatment B (lasmidi tan + pl acebo) .
[IP_ADDRESS]. Cardiovascular Parameter Estimation
The primary  parameters for the cardiovascular analyses will be peak hourly  meanvalues of SBP, 
DBP, and MAP, and nadir hourly  mean value of PR,and will be determined by [CONTACT_44117].
[IP_ADDRESS]. Statistical Inference of Cardiovascular Parameters
Cardi ovascular parameters will be listed, and summarized using descriptive statist ics, as 
appropriate.
Baseline value will be defined as the peak mean value during the [ADDRESS_178821] of a single dose of sumatriptan 100 mg on the cardi ovascular 
param eters of lasmidi tan. A repeated measures linear mixed -effects m odel with baseline as a 
covari ate, fixed effects for time point, treatment, period (1, 2, 3, or 4), treatment sequence ,and 
the treatment by t ime po int interaction, and a random effect for subject will be used. Least 
squares (LS) means and treatment differences ([lasmiditan + sumatriptan] -
[lasmidi tan+placebo]) will be calculated and presented with the corresponding CIs. The same 
model will be used to assess the impact of a single dose of lasmiditan 200 mg on the 
cardi ovascular param eters of sum atriptan.
Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
H8H-MC-LAHU (c) Clinical Pharmacology Protocol Page 56
LY573144Protocol H8H -MC -LAHU Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a 19.[ADDRESS_178822] 5 3 15
Lasmiditan and metabolite 
pharmacokinetic s2 56 112
Sumatriptan pharmacokinetic s 3 45 135
Renal biomarkers 2.5 56 140
Pharmacogenetics 10 1 10
Total 494
Total for clinical purposes (rounded up to the nearest 10 mL) 500
aAdditional samples may be drawn if needed for safety purposes.
[COMPANY_003]Leo Document ID = d90b545b-bf55-413e-bff8-e4fb2b5a9925
Approver: 
Approval Date & Time: 19-Oct-2017 17:16:34 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 20-Oct-2017 08:36:25 GMT
Signature [CONTACT_32869]: Approved[COMPANY_003]